

ATCC

10801 University Blvd • Manassas, VA 20110-2209 • Telephone: 703-365-2700 • FAX: 703-365-2745

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3 AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

Department of Justice
Attn: Natalie T. Lu
810 Seventh Street, NW
Washington, DC 20531

Deposited on Behalf of: Department of Justice, Washington, DC

Identification Reference by Depositor:

Patent Deposit Designation

Mouse Hybridoma Cell Line: 181A356.1

PTA-5096

The deposit was accompanied by: a scientific description a proposed taxonomic description indicated above.

The deposit was received March 28, 2003 by this International Depository Authority and has been accepted.

AT YOUR REQUEST: X We will inform you of requests for the strain for 30 years.

The strain will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strain, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strain.


If the culture should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace it with living culture of the same.

The strain will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the culture cited above was tested May 20, 2003. On that date, the culture was viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:



Marie Harris, Patent Specialist, ATCC Patent Depository

Date: June 2, 2003

cc: Jon Tornquist

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Lu, Natalie
Art Unit	
Examiner Name	
Attorney Docket Number	27-8915

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	Lu, Natalie T.
				Art Unit	
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	27 - 8915

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		LU, NATALIE, "Distinguishing Crack Use From Powder Cocaine: Identification of Unique Pyrolysis Products from Crack Use In Urine", April 26 - 30, 1999.			
		JACOB, PEYTON III, et al., "A pyrolysis Product, Anhydroecgonine Methyl Ester (Methylecgonidine), is in the Urine of Cocaine Smokers", Journal of Analytical Toxicology, Vol.14, Nov/Dec 1990			
		CONE, EDWARD J., et al., "simultaneous Measurement of Cocaine, Cocaethylene, Their Metabolites, and "Crack" Pyrolysis Products by Gas Chromatography-Mass Spectrometry", 1994, pp 1299-1305, Vol.40/7			
		LEVINE, BARRY, et al., "Stability of Ecgonine Methyl Ester in Postmortem Urine Specimens", Journal of Forensic Sciences, JFSCA, Vol. 41, No. 1, January 1996, pp 126-128.			
		RILEY, K. JACK, NATALIE T. LU, ET AL., "Monitoring the Crack Epidemic through Urine Testing: Establishment of Routine Detection Methods", Addiction Biology, 2001, pp 83 - 95.			
		PASCAL, KINTZ, et al., "Testing Human Hair and Urine for Anhydroecgonine Methyl Ester, a Pyrolysis Product of Cocaine", Journal of Analytical Toxicology, Vol. 19, October 1995 pp479-482.			
		CONE, EDWARD, "Validity of Commercial Urine Cocaine Metabolite Assays: III. Evaluation of an Enzyme-Linke Immunosorbent Assay (ELISA) for Detection of Cocaine and Cocaine Metabolite" Journal of Forensic Sciences, Vol. 34, No. 4, July 1989, pp991-995.			
		CONE, EDWARD, et al., "Validity Testing of Commercial Urine Cocaine Metabolite Assays: IV. Evaluation of the EMIT d.a.u. Cocaine Metabolite Assay in Quantitative Mode for Detection of Cocaine Metabolite, Journal of Forensic Sciences, Vol. 35, No. 4, July 1990, pp. 786 - 791.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	Lu Natalie T.
				Art Unit	
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	27 - 8915

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		ROMBERG, ROBERT W. and Past, M.R., "Reanalysis of Forensic Urine Specimens Containing Benzoylecgonine and THC-COOH",			
		Journal of Forensic Sciences, Vol. 39, No. 2, March 1994 pp. 479-485.			
		JEFFCOAT, ROBERT A., et. al., "Cocaine Disposition in Humans After Intravenous Injection, Nasal Insufflation (Snorting), or Smoking". Drug Metabolism and Disposition, Vol. 17. No. 2. 1989 pp. 153-159.			
		MARTINEZ, FRANCISCA, et. al., "Cocaine Metabolite (Benzoylecgonine) in Hair and Urine of Drug Users, "Journal of Analytical Toxicology, Vol. 17, May/June 1993, pp. 138-142.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.